{"adverse_reactions":["ADVERSE REACTIONS"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY"],"contraindications":["CONTRAINDICATIONS"],"description":["DESCRIPTION"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION"],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE"],"effective_time":"20180912","id":"75b0c827-08e6-e445-e053-2991aa0a2141","indications_and_usage":["INDICATIONS AND USAGE Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets, USP are recommended even where the incidence of postoperative nausea and/or vomiting is low."],"openfda":{},"overdosage":["OVERDOSAGE"],"package_label_principal_display_panel":["PACKAGE LABEL-PRINCIPAL DISPLAY PANEL ONDANESTRON 4 mg","10"],"set_id":"2ebdb67e-d584-0f7b-e054-00144ff8d46c","spl_product_data_elements":["ONDANSETRON ONDANSETRON ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE MAGNESIUM STEARATE STARCH, CORN TITANIUM DIOXIDE HYPROMELLOSE 2910 (6 MPA.S) TRIACETIN ONDANSETRON HYDROCHLORIDE ONDANSETRON WHITE TO OFF WHITE F;91"],"version":"2","warnings":["WARNINGS"]}